Tempest Therapeutics, Inc. (TPST) announced on Thursday the extension of its existing stockholder rights plan through the upcoming Annual Meeting of Stockholders. CEO Stephen Brady explained that this strategic move aims to ensure that all stockholders can benefit from the long-term value of their investments. Additionally, the plan seeks to minimize the risk of any individual or group gaining control of Tempest through purchasing shares on the open market. As of now, Tempest's shares are trading at $1.36, marking a 1.41% increase on the Nasdaq.